The biotechnology sector is undergoing significant changes, facing major structural and technological challenges. The "patent cliff" continues to threaten industry revenues, potentially resulting in a $400 billion loss, while the integration of artificial intelligence (AI) into research and development (R&D) processes emerges as an essential solution to maintain competitiveness. Recent advancements, such as Stanford's use of AI Evo 2 to generate phages against E. coli, illustrate the transformative potential of these technologies, though they also raise security and ethical concerns.